Ichthyosis Market Trends Point to Steady Growth Ahead by 2032, DelveInsight Analysis Reveals

DelveInsight's "Ichthyosis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Ichthyosis, historical and forecasted epidemiology as well as the Ichthyosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Ichthyosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ichthyosis Market Forecast
https://www.delveinsight.com/sample-request/ichthyosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Ichthyosis Market Report:
• The Ichthyosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In January 2025, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, has reported additional positive interim data from its ongoing clinical study for Netherton Syndrome. The company previously shared promising results from the first subject dosed twice daily with QRX003 at the six-week midpoint. Now, Quoin has released clinical data following the full 12-week treatment period, highlighting significant improvements across all measured clinical endpoints. The observed results further support the potential efficacy of QRX003 in treating Netherton Syndrome, reinforcing its role as a promising therapeutic candidate for this rare condition.
• In August 2024, Timber Pharmaceuticals Inc., a LEO Pharma company, has released findings from the randomized, double-blind 12-week phase of the ASCEND trial. The study did not demonstrate a statistically significant difference in response rates between patients treated with TMB-001 and those receiving the vehicle after 12 weeks. ASCEND is a Phase 3 clinical trial evaluating TMB-001, an investigational topical isotretinoin formulation, as a potential treatment for moderate to severe congenital ichthyosis.
• In March 2024, Timber Pharmaceuticals, Inc., a subsidiary of LEO Pharma, presented preliminary findings from the ASCEND trial during a late-breaking session at the 2024 American Academy of Dermatology (AAD) Annual Meeting. The ASCEND trial evaluates TMB-001, an investigational polyethylene glycol (iPEGTM)-based topical isotretinoin, being developed to treat moderate-to-severe X-linked and autosomal recessive congenital ichthyosis (CI). CI is a group of rare genetic keratinization disorders characterized by dry, thickened, and scaling skin. Currently, no FDA-approved treatments are available specifically for CI.
• Ichthyosis affects approximately 1 in 250,000 births for the most severe forms, while milder forms like Ichthyosis vulgaris occur in about 1 in 250 to 1 in 1,000 people.
• There are more than 20 different types of ichthyosis, including Ichthyosis vulgaris, X-linked ichthyosis, and Harlequin ichthyosis.
• Most types are inherited in an autosomal dominant or recessive manner, while some can be acquired due to underlying conditions.
• X-linked ichthyosis primarily affects males, while other forms occur in both genders.
• Key Ichthyosis Companies: Timber Pharmaceuticals, Krystal Biotech, GSK, Timber Pharmcecuticals, Janssen Scientific, Patagonia Pharma, Timber Pharmcuticals, Crown Laboratories, Inc, and others
• Key Ichthyosis Therapies: TMB-001, KB105, Liarozole, TMB-001, Ustekinumab, PAT-001, Isotretinoin, 146-9251, and others
• The Ichthyosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ichthyosis pipeline products will significantly revolutionize the Ichthyosis market dynamics.

Ichthyosis Overview
Ichthyosis is a group of rare genetic skin disorders characterized by dry, scaly, thickened, or flaky skin due to abnormal skin cell shedding and renewal. It results from mutations affecting skin barrier function, leading to excessive keratin buildup. Symptoms can range from mild dryness to severe scaling and cracking, often causing discomfort and an increased risk of infections. The condition may be present at birth or develop later in life. While there is no cure, treatment focuses on managing symptoms through moisturizing creams, keratolytic agents, and, in some cases, systemic therapies to improve skin hydration and reduce scaling.

Get a Free sample for the Ichthyosis Market Report
https://www.delveinsight.com/report-store/ichthyosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ichthyosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ichthyosis Epidemiology Segmentation:
The Ichthyosis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Ichthyosis
• Prevalent Cases of Ichthyosis by severity
• Gender-specific Prevalence of Ichthyosis
• Diagnosed Cases of Episodic and Chronic Ichthyosis

Download the report to understand which factors are driving Ichthyosis epidemiology trends @ Ichthyosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/ichthyosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ichthyosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ichthyosis market or expected to get launched during the study period. The analysis covers Ichthyosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ichthyosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ichthyosis Therapies and Key Companies
• TMB-001: Timber Pharmaceuticals
• KB105: Krystal Biotech
• Liarozole: GSK
• TMB-001: Timber Pharmcecuticals
• Ustekinumab: Janssen Scientific
• PAT-001: Patagonia Pharma
• Isotretinoin: Timber Pharmcuticals
• 146-9251: Crown Laboratories, Inc

Discover more about therapies set to grab major Ichthyosis market share @ Ichthyosis Treatment Market
https://www.delveinsight.com/sample-request/ichthyosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ichthyosis Market Strengths
• Ongoing Search for Cure - Along with clinical trials in Ichthyosis, various institute/ organization/ and groups are conducting research to find cure for this disease.
• Various Organization and Foundation Support - Organizations and government level support has aided in further development of angleman syndrome treatment

Ichthyosis Market Opportunities
• Lack of treatment protocols
• Research funding
• Biomarker research
• Integrative and novel therapies

Scope of the Ichthyosis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ichthyosis Companies: Timber Pharmaceuticals, Krystal Biotech, GSK, Timber Pharmcecuticals, Janssen Scientific, Patagonia Pharma, Timber Pharmcuticals, Crown Laboratories, Inc, and others
• Key Ichthyosis Therapies: TMB-001, KB105, Liarozole, TMB-001, Ustekinumab, PAT-001, Isotretinoin, 146-9251, and others
• Ichthyosis Therapeutic Assessment: Ichthyosis current marketed and Ichthyosis emerging therapies
• Ichthyosis Market Dynamics: Ichthyosis market drivers and Ichthyosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Ichthyosis Unmet Needs, KOL's views, Analyst's views, Ichthyosis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.